tiprankstipranks
Advertisement
Advertisement

HK:9926 Stock Latest News

Akeso Schedules Board Meeting to Approve 2026 Interim Results
Company AnnouncementsAkeso Schedules Board Meeting to Approve 2026 Interim Results
4d ago
Summit says Akeso receives marketing authorization in China for ivonescimab
PremiumThe Fly
Summit says Akeso receives marketing authorization in China for ivonescimab
5d ago
SMMT
Akeso Wins Third NMPA Nod for Ivonescimab in Advanced Lung Cancer
PremiumCompany Announcements
Akeso Wins Third NMPA Nod for Ivonescimab in Advanced Lung Cancer
9d ago
Akeso Advances AK138D1 Lung Cancer Trial, Keeping Pipeline Momentum in Focus
PremiumCompany Announcements
Akeso Advances AK138D1 Lung Cancer Trial, Keeping Pipeline Momentum in Focus
23d ago
9926
Akeso Grants New Share Options to Boost Long-Term Incentives
PremiumCompany Announcements
Akeso Grants New Share Options to Boost Long-Term Incentives
26d ago
Akeso’s New Phase II Breast Cancer Trial Signals Fresh Upside Potential
PremiumCompany AnnouncementsAkeso’s New Phase II Breast Cancer Trial Signals Fresh Upside Potential
1M ago
9926
Akeso’s New Phase II Lung Cancer Trial: What Investors Should Watch
Premium
Company Announcements
Akeso’s New Phase II Lung Cancer Trial: What Investors Should Watch
1M ago
9926
Akeso’s AK104 Kidney Cancer Trial Completion: What Investors Should Watch Next
Premium
Company Announcements
Akeso’s AK104 Kidney Cancer Trial Completion: What Investors Should Watch Next
2M ago
9926
Akeso Shareholders Approve All Resolutions at 2026 AGM, Renewing Board Mandates and Capital Powers
PremiumCompany Announcements
Akeso Shareholders Approve All Resolutions at 2026 AGM, Renewing Board Mandates and Capital Powers
2M ago
Akeso’s Ebronucimab Manufacturing Study Reaches Completion, Trimming Risk in a Crowded Cholesterol Market
PremiumCompany Announcements
Akeso’s Ebronucimab Manufacturing Study Reaches Completion, Trimming Risk in a Crowded Cholesterol Market
2M ago
9926
Akeso Wins China NMPA Approval for IL-17 Antibody Gumokimab in Psoriasis
PremiumCompany Announcements
Akeso Wins China NMPA Approval for IL-17 Antibody Gumokimab in Psoriasis
2M ago
Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes
PremiumCompany Announcements
Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes
2M ago
Akeso’s AK104 Lung Cancer Trial Completion: What Investors Should Watch Next
PremiumCompany AnnouncementsAkeso’s AK104 Lung Cancer Trial Completion: What Investors Should Watch Next
2M ago
9926
Akeso Sets 2026 AGM to Approve Accounts, Board Slate and Capital-Issuance Mandate
Premium
Company Announcements
Akeso Sets 2026 AGM to Approve Accounts, Board Slate and Capital-Issuance Mandate
3M ago
Akeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
Premium
Company Announcements
Akeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
3M ago
Akeso: Robust FY25 Execution and Late‑Stage Oncology Pipeline Drive Upside and Higher Target Price
PremiumRatings
Akeso: Robust FY25 Execution and Late‑Stage Oncology Pipeline Drive Upside and Higher Target Price
5M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
5M ago
RADX
SMMT
Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026
PremiumThe Fly
Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026
5M ago
SMMT
Akeso Boosts Revenue and R&D While Trimming Adjusted EBITDA Loss in 2025
PremiumCompany Announcements
Akeso Boosts Revenue and R&D While Trimming Adjusted EBITDA Loss in 2025
5M ago
Akeso Advances Dual-Antibody Cancer Trial, Keeping Oncology Pipeline in Focus
PremiumCompany AnnouncementsAkeso Advances Dual-Antibody Cancer Trial, Keeping Oncology Pipeline in Focus
5M ago
9926
Akeso’s AK120 Phase II Completion Adds New Momentum to Its Atopic Dermatitis Pipeline
Premium
Company Announcements
Akeso’s AK120 Phase II Completion Adds New Momentum to Its Atopic Dermatitis Pipeline
5M ago
9926
Akeso Schedules Board Meeting to Approve 2025 Annual Results
Premium
Company Announcements
Akeso Schedules Board Meeting to Approve 2025 Annual Results
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >